Company intelligence / Profile preview
Kaida BioPharma
Fort Lauderdale, Florida, United Stateskaida-biopharma.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
KAD101 has demonstrated encouraging results in a human clinical study with all patients showing tumor reduction with a clean safety profile as a daily injectable. Three patients in early trials showed tumor reduction, with one patient's tumor shrinking to non-measurable size.
- Therapeutic areas
- Oncology
- Modalities
- BiologicsGrowth hormone antagonists
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
Collaboration with Dr. John Langenheim (Thomas Jefferson University) and Dr. Anil Sood (MD Anderson)
Beyond the preview
Go deeper on Kaida BioPharma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Kaida BioPharma.